Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review

Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2016-04, Vol.95 (14), p.e3150-e3150
Hauptverfasser: Liu, Jing, Sun, Bingbing, Yin, Huijun, Liu, Sijin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e3150
container_issue 14
container_start_page e3150
container_title Medicine (Baltimore)
container_volume 95
creator Liu, Jing
Sun, Bingbing
Yin, Huijun
Liu, Sijin
description Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (e.g., iron-deficiency anemia and anemia of chronic diseases) and iron overload diseases, such as hereditary hemochromatosis and β-thalassemia. Hepcidin (encoded by Hamp gene) is a peptide hormone synthesized by hepatocytes, and it plays an important role in regulating the systematic iron homeostasis. As the systemic iron regulator, hepcidin, not only controls dietary iron absorption and iron egress out of iron storage cells, but also induces iron redistribution in various organs. Deregulated hepcidin is often seen in a variety of iron-related diseases including anemias and iron overload disorders. In the case of iron overload disorders (e.g., hereditary hemochromatosis and β-thalassemia), hepatic hepcidin concentration is significantly reduced.Since hepcidin deregulation is responsible for iron disorder-associated diseases, the purpose of this review is to summarize the recent findings on therapeutics targeting hepcidin.Continuous efforts have been made to search for hepcidin mimics and chemical compounds that could be used to increase hepcidin level. Here, a literature search was conducted in PubMed, and research papers relevant to hepcidin regulation or hepcidin-centered therapeutic work were reviewed. On the basis of literature search, we recapitulated recent findings on therapeutic studies targeting hepcidin, including agonists and antagonists to modulate hepcidin expression or its downstream signaling. We also discussed the molecular mechanisms by which hepcidin level and iron metabolism are modulated.Elevating hepcidin concentration is an optimal strategy to ameliorate iron overload diseases, and also to relieve β-thalassemia phenotypes by improving ineffective erythropoiesis. Relative to the current conventional therapies, such as phlebotomy and blood transfusion, therapeutics targeting hepcidin would open a new avenue for treatment of iron-related diseases.
doi_str_mv 10.1097/MD.0000000000003150
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4998755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27057839</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2855-9cc2073be2e7edaf489ed24da9c1a8fdc2ddf213163897ad09f46d6fc353b65d3</originalsourceid><addsrcrecordid>eNpdkd1KAzEQhYMotv48gSD7Alvzu9l4IYhVK1gUrdchTWbb6Ha3JNuWvr1bq0Wdm4GZc76BMwidEdwjWMmLYb-HfxUjAu-hLhEsS4XK-D7qYkxFKpXkHXQU4zvGhEnKD1GHSixkzlQXPQ9gbr3z1WVynTyHeuajrybJaArBzGHReJuMTJhAkxR1SB5CXSV9H-vgIMSN5XUdG5iZje4Flh5WJ-igMGWE0-9-jN7ubkc3g_Tx6f7h5voxtTQXIlXWUizZGChIcKbguQJHuTPKEpMXzlLnCkoYyViupHFYFTxzWWGZYONMOHaMrrbc-WI8A2ehaoIp9Tz4mQlrXRuv_24qP9WTeqm5UrkUogWwLcCGOsYAxc5LsN4ErId9_T_g1nX---zO85NoK-Bbwaoumzakj3KxgqCnYMpm-sUTUtGUYpJhjgVO20n7s0_JPod0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Liu, Jing ; Sun, Bingbing ; Yin, Huijun ; Liu, Sijin</creator><creatorcontrib>Liu, Jing ; Sun, Bingbing ; Yin, Huijun ; Liu, Sijin</creatorcontrib><description>Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (e.g., iron-deficiency anemia and anemia of chronic diseases) and iron overload diseases, such as hereditary hemochromatosis and β-thalassemia. Hepcidin (encoded by Hamp gene) is a peptide hormone synthesized by hepatocytes, and it plays an important role in regulating the systematic iron homeostasis. As the systemic iron regulator, hepcidin, not only controls dietary iron absorption and iron egress out of iron storage cells, but also induces iron redistribution in various organs. Deregulated hepcidin is often seen in a variety of iron-related diseases including anemias and iron overload disorders. In the case of iron overload disorders (e.g., hereditary hemochromatosis and β-thalassemia), hepatic hepcidin concentration is significantly reduced.Since hepcidin deregulation is responsible for iron disorder-associated diseases, the purpose of this review is to summarize the recent findings on therapeutics targeting hepcidin.Continuous efforts have been made to search for hepcidin mimics and chemical compounds that could be used to increase hepcidin level. Here, a literature search was conducted in PubMed, and research papers relevant to hepcidin regulation or hepcidin-centered therapeutic work were reviewed. On the basis of literature search, we recapitulated recent findings on therapeutic studies targeting hepcidin, including agonists and antagonists to modulate hepcidin expression or its downstream signaling. We also discussed the molecular mechanisms by which hepcidin level and iron metabolism are modulated.Elevating hepcidin concentration is an optimal strategy to ameliorate iron overload diseases, and also to relieve β-thalassemia phenotypes by improving ineffective erythropoiesis. Relative to the current conventional therapies, such as phlebotomy and blood transfusion, therapeutics targeting hepcidin would open a new avenue for treatment of iron-related diseases.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000003150</identifier><identifier>PMID: 27057839</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Hepcidins - drug effects ; Hepcidins - physiology ; Homeostasis ; Humans ; Iron - physiology ; Iron Metabolism Disorders - drug therapy ; Iron Metabolism Disorders - etiology ; Systematic Review And Meta-Analysis</subject><ispartof>Medicine (Baltimore), 2016-04, Vol.95 (14), p.e3150-e3150</ispartof><rights>Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2855-9cc2073be2e7edaf489ed24da9c1a8fdc2ddf213163897ad09f46d6fc353b65d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998755/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998755/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27057839$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>Sun, Bingbing</creatorcontrib><creatorcontrib>Yin, Huijun</creatorcontrib><creatorcontrib>Liu, Sijin</creatorcontrib><title>Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (e.g., iron-deficiency anemia and anemia of chronic diseases) and iron overload diseases, such as hereditary hemochromatosis and β-thalassemia. Hepcidin (encoded by Hamp gene) is a peptide hormone synthesized by hepatocytes, and it plays an important role in regulating the systematic iron homeostasis. As the systemic iron regulator, hepcidin, not only controls dietary iron absorption and iron egress out of iron storage cells, but also induces iron redistribution in various organs. Deregulated hepcidin is often seen in a variety of iron-related diseases including anemias and iron overload disorders. In the case of iron overload disorders (e.g., hereditary hemochromatosis and β-thalassemia), hepatic hepcidin concentration is significantly reduced.Since hepcidin deregulation is responsible for iron disorder-associated diseases, the purpose of this review is to summarize the recent findings on therapeutics targeting hepcidin.Continuous efforts have been made to search for hepcidin mimics and chemical compounds that could be used to increase hepcidin level. Here, a literature search was conducted in PubMed, and research papers relevant to hepcidin regulation or hepcidin-centered therapeutic work were reviewed. On the basis of literature search, we recapitulated recent findings on therapeutic studies targeting hepcidin, including agonists and antagonists to modulate hepcidin expression or its downstream signaling. We also discussed the molecular mechanisms by which hepcidin level and iron metabolism are modulated.Elevating hepcidin concentration is an optimal strategy to ameliorate iron overload diseases, and also to relieve β-thalassemia phenotypes by improving ineffective erythropoiesis. Relative to the current conventional therapies, such as phlebotomy and blood transfusion, therapeutics targeting hepcidin would open a new avenue for treatment of iron-related diseases.</description><subject>Hepcidins - drug effects</subject><subject>Hepcidins - physiology</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Iron - physiology</subject><subject>Iron Metabolism Disorders - drug therapy</subject><subject>Iron Metabolism Disorders - etiology</subject><subject>Systematic Review And Meta-Analysis</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkd1KAzEQhYMotv48gSD7Alvzu9l4IYhVK1gUrdchTWbb6Ha3JNuWvr1bq0Wdm4GZc76BMwidEdwjWMmLYb-HfxUjAu-hLhEsS4XK-D7qYkxFKpXkHXQU4zvGhEnKD1GHSixkzlQXPQ9gbr3z1WVynTyHeuajrybJaArBzGHReJuMTJhAkxR1SB5CXSV9H-vgIMSN5XUdG5iZje4Flh5WJ-igMGWE0-9-jN7ubkc3g_Tx6f7h5voxtTQXIlXWUizZGChIcKbguQJHuTPKEpMXzlLnCkoYyViupHFYFTxzWWGZYONMOHaMrrbc-WI8A2ehaoIp9Tz4mQlrXRuv_24qP9WTeqm5UrkUogWwLcCGOsYAxc5LsN4ErId9_T_g1nX---zO85NoK-Bbwaoumzakj3KxgqCnYMpm-sUTUtGUYpJhjgVO20n7s0_JPod0</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Liu, Jing</creator><creator>Sun, Bingbing</creator><creator>Yin, Huijun</creator><creator>Liu, Sijin</creator><general>Wolters Kluwer Health, Inc. All rights reserved</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20160401</creationdate><title>Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review</title><author>Liu, Jing ; Sun, Bingbing ; Yin, Huijun ; Liu, Sijin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2855-9cc2073be2e7edaf489ed24da9c1a8fdc2ddf213163897ad09f46d6fc353b65d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Hepcidins - drug effects</topic><topic>Hepcidins - physiology</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Iron - physiology</topic><topic>Iron Metabolism Disorders - drug therapy</topic><topic>Iron Metabolism Disorders - etiology</topic><topic>Systematic Review And Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Jing</creatorcontrib><creatorcontrib>Sun, Bingbing</creatorcontrib><creatorcontrib>Yin, Huijun</creatorcontrib><creatorcontrib>Liu, Sijin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Jing</au><au>Sun, Bingbing</au><au>Yin, Huijun</au><au>Liu, Sijin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>95</volume><issue>14</issue><spage>e3150</spage><epage>e3150</epage><pages>e3150-e3150</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Iron is required for most forms of organisms, and it is the most essential element for the functions of many iron-containing proteins involved in oxygen transport, cellular respiration, DNA replication, and so on. Disorders of iron metabolism are associated with diverse diseases, including anemias (e.g., iron-deficiency anemia and anemia of chronic diseases) and iron overload diseases, such as hereditary hemochromatosis and β-thalassemia. Hepcidin (encoded by Hamp gene) is a peptide hormone synthesized by hepatocytes, and it plays an important role in regulating the systematic iron homeostasis. As the systemic iron regulator, hepcidin, not only controls dietary iron absorption and iron egress out of iron storage cells, but also induces iron redistribution in various organs. Deregulated hepcidin is often seen in a variety of iron-related diseases including anemias and iron overload disorders. In the case of iron overload disorders (e.g., hereditary hemochromatosis and β-thalassemia), hepatic hepcidin concentration is significantly reduced.Since hepcidin deregulation is responsible for iron disorder-associated diseases, the purpose of this review is to summarize the recent findings on therapeutics targeting hepcidin.Continuous efforts have been made to search for hepcidin mimics and chemical compounds that could be used to increase hepcidin level. Here, a literature search was conducted in PubMed, and research papers relevant to hepcidin regulation or hepcidin-centered therapeutic work were reviewed. On the basis of literature search, we recapitulated recent findings on therapeutic studies targeting hepcidin, including agonists and antagonists to modulate hepcidin expression or its downstream signaling. We also discussed the molecular mechanisms by which hepcidin level and iron metabolism are modulated.Elevating hepcidin concentration is an optimal strategy to ameliorate iron overload diseases, and also to relieve β-thalassemia phenotypes by improving ineffective erythropoiesis. Relative to the current conventional therapies, such as phlebotomy and blood transfusion, therapeutics targeting hepcidin would open a new avenue for treatment of iron-related diseases.</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>27057839</pmid><doi>10.1097/MD.0000000000003150</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2016-04, Vol.95 (14), p.e3150-e3150
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4998755
source MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Hepcidins - drug effects
Hepcidins - physiology
Homeostasis
Humans
Iron - physiology
Iron Metabolism Disorders - drug therapy
Iron Metabolism Disorders - etiology
Systematic Review And Meta-Analysis
title Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A28%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepcidin:%20A%20Promising%20Therapeutic%20Target%20for%20Iron%20Disorders:%20A%20Systematic%20Review&rft.jtitle=Medicine%20(Baltimore)&rft.au=Liu,%20Jing&rft.date=2016-04-01&rft.volume=95&rft.issue=14&rft.spage=e3150&rft.epage=e3150&rft.pages=e3150-e3150&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000003150&rft_dat=%3Cpubmed_cross%3E27057839%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27057839&rfr_iscdi=true